Lucentis intravitreal injection — Competitive Intelligence Brief

Lucentis intravitreal injection (Lucentis intravitreal injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF-A inhibitor (monoclonal antibody fragment). Area: Ophthalmology.

phase 3 VEGF-A inhibitor (monoclonal antibody fragment) VEGF-A Ophthalmology Small molecule

Target snapshot

Lucentis intravitreal injection (Lucentis intravitreal injection) — Medical University of Vienna. Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce vascular permeability in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lucentis intravitreal injection TARGET	Lucentis intravitreal injection	Medical University of Vienna	phase 3	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A
Ketorolac + Ranibizumab	Ketorolac + Ranibizumab	Università degli Studi di Brescia	marketed	NSAID + anti-VEGF monoclonal antibody fragment	COX enzymes (ketorolac); VEGF-A (ranibizumab)
Lucentis (Treat and extend)	Lucentis (Treat and extend)	Retinal Consultants of Arizona	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A
Rescue Intravitreal Aflibercept Injection	Rescue Intravitreal Aflibercept Injection	Southeast Retina Center, Georgia	marketed	VEGF inhibitor / Recombinant fusion protein	VEGF-A, VEGF-B, PlGF (placental growth factor)
Aflibercept (Eylea)	Aflibercept (Eylea)	Ahmad Zeeshan Jamil	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Aflibercept and ranibizumab	Aflibercept and ranibizumab	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (and VEGF-B for aflibercept)
Ranibizumab and Aflibercept	Ranibizumab and Aflibercept	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (vascular endothelial growth factor-A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF-A inhibitor (monoclonal antibody fragment) class)

1. Retinal Consultants of Arizona · 2 drugs in this class
2. Ain Shams University · 1 drug in this class
3. Greater Houston Retina Research · 1 drug in this class
4. Hoffmann-La Roche · 1 drug in this class
5. LEANDRO CABRAL ZACHARIAS · 1 drug in this class
6. Medical University of Vienna · 1 drug in this class
7. AbbVie · 1 drug in this class
8. Samsung Bioepis Co., Ltd. · 1 drug in this class